The recommended starting dose based on clinical trial protocols is 2mg once weekly
These items are not pharmaceuticals or medications, and the Food and Drug Administration has not given permission for the treatment or prevention of any disease, medical condition, or ailment using them
Semaglutide is being investigated in 2 large phase III clinical trial programs in obesity: the STEP program, directed toward regulatory approval of semaglutide as an antiobesity drug, and SELECT (NCT03574597), evaluating cardiovascular outcomes in 17,500 patients
Semaglutide, despite the largest cohort (n=992,660), had a relatively low risk (0.039%)
Heatmap proteomics representation For heatmap of known ferroptosis genes from Stockwell [1], individual log 2 samples were divided by the sum of each row and clustered by Euclidean distance using Gene Cluster 3 [93]